Funding for this research was provided by:
Ministry of Science, ICT and Future Planning (NRF-2015R1A2A01004202, NRF-2018R1A2A2A05018319)
Ministry of Trade, Industry and Energy (10078367)
Received: 28 October 2018
Accepted: 14 August 2019
First Online: 20 August 2019
Ethics approval and consent to participate
: All experimental protocols and procedures were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Ethics Committee and the Institutional Animal Care and Use Committee of Korea University College of Medicine (Approval No. KOREA-2016-0041).
: Not applicable.
: Shinpoong Pharmaceutical Company recently acquired a license from Korea University to develop SP-8356 as an anti-atherosclerotic drug. The authors declare that they have no competing interests.